Orexigen Thinks Contrave On The Verge Of Approval, Again
This article was originally published in The Pink Sheet Daily
The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.
You may also be interested in...
The biotech finally gleaned an FDA approval for its obesity pill Contrave and now faces the hurdle of commercialization, but plans to profit by the lessons from its competitors’ missteps.
The biotech finally gains approval for its obesity agent and receives a label from FDA that, despite multiple contraindications and a boxed warning, is being looked upon favorably.
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.